A mutation in the ␥ 2 subunit of the ␥-aminobutyric acid (GABA) type A receptor (GABAR), which changes an arginine to a glutamine at position 43 (R43Q), is linked to familial idiopathic epilepsies. We used radioligand binding, immunoblotting, and immunofluorescence techniques to examine the properties of wild-type ␣ 1 ␤ 2 ␥ 2 and mutant ␣ 1 ␤ 2 ␥ 2 R43Q GABARs expressed in HEK 293 cells. The ␥ 2 R43Q mutation had no affect on the binding affinity of the benzodiazepine flunitrazepam. However, in cells expressing ␣ 1 ␤ 2 ␥ 2 R43Q GABARs, the number of binding sites for [
Idiopathic partial and generalized epilepsies are the most common forms of heritable seizure disorders, accounting for 40% of all epilepsies (1) . Idiopathic epilepsies are those seizure disorders that are not preceded by or concomitant with trauma or other disorders but are due mainly to genetic factors. Because of the ubiquitous role of the neurotransmitter GABA 1 in mediating cortical inhibition, deficits in GABAergic transmission have long been surmised to play a role in the pathogenesis of epilepsy. Recently, several mutations in the GABA A receptor (GABAR) have been identified through the use of genetic linkage analysis in families with idiopathic generalized epilepsies.
GABARs are heteropentameric ligand gated chloride channels that mediate fast synaptic inhibition in the brain. The receptors are assembled from a number of different subunits and subunit isoforms, including ␣ 1-6 , ␤ 1-3 , ␥ 1-3 , ␦, ⑀, , and (2, 3). The majority of GABARs in the brain are believed to consist of 2 ␣, 2 ␤, and 1 ␥ subunits (4, 5) . The inclusion of a ␥ subunit confers benzodiazepine (BZD) sensitivity to GABARs (6) and also influences receptor expression, synaptic targeting, and trafficking (7, 8) . To date, four mutations in the ␥ 2 subunit of the GABAR (missense mutations R43Q and K289M, the nonsense mutation Q351X, and the anomalous splice-donor site mutation IVS6 ϩ 2T 3 G) and one mutation in the ␣ 1 subunit of the receptor (missense mutation A322D) have been associated with idiopathic epileptic syndromes (9 -13) .
Several groups have explored the effects of the ␥ 2 R43Q mutation on GABAR function. Using recombinant GABAR expression in Xenopus laevis oocytes and two-electrode voltage clamp recording techniques, no differences in GABA EC 50 values between wild-type (WT)␣ 1 ␤ 2 ␥ 2 and mutant ␣ 1 ␤ 2 ␥ 2 R43Q receptors were observed (13) . However, the ability of the BZDs flunitrazepam (FNZM) and diazepam to potentiate GABA-activated current was reduced in mutant receptors (13, 14) . Recombinant receptor expression in HEK 293 cells combined with patchclamping and rapid drug application techniques demonstrated that the ␥ 2 R43Q mutation slowed GABAR deactivation and speeded desensitization (14) . In contrast, another study using expression in HEK 293 cells and similar recording techniques reported no differences in receptor kinetics or diazepam potentiation of GABA current between mutant and WT receptors but instead observed reductions in maximal GABA-induced current in cells expressing mutant receptors (15) .
In the present study, we used radioligand binding, immunoblotting, and immunofluorescence techniques to clarify and further characterize the properties of WT ␣ 1 ␤ 2 ␥ 2 and mutant ␣ 1 ␤ 2 ␥ 2 R43Q GABA A receptors expressed in HEK 293 cells. Several facets of GABAR function were examined, including receptor cell surface expression, receptor pharmacology, and functional coupling between the GABA and BZD binding sites. Here, we report that the ␥ 2 R43Q mutation reduces surface expression of ␣ 1 ␤ 2 ␥ 2 R43Q receptors while leaving the pharmacology and functional coupling between GABA and BZD binding sites of the receptor intact.
EXPERIMENTAL PROCEDURES

Transient Expression in HEK 293
Cells-Wild-type ␣ 1 , ␤ 2 , ␥ 2s , and mutant ␥ 2 R43Q subunit cDNAs in pcDNA3.1 encoding for human GABA receptor protein were obtained from Dr. Steve Petrou (University of Melbourne, Victoria, Australia). Subunit cDNAs were verified by double-stranded DNA sequencing. HEK 293 cells were grown as described previously (16) . Cells were co-transfected at ϳ70% confluency with ␣ 1 , ␤ 2 , ␥ 2 , and mutant ␥ 2 R43Q subunit cDNAs and the vector pAdvantage (Promega) at a ratio of 1:1:1:1.5 (4 g of DNA per subunit and 6 g of pAdvantage per dish) using a standard CaHPO 4 precipitation method (17) .
Radioligand Binding-Cells were harvested 48 h after transfection, membrane homogenates were prepared, and homologous competition binding experiments were performed as described in Boileau et al. (16 To measure GABA potentiation of [ 3 H]FNZM binding, membrane homogenates (100 g) were incubated for 20 min at 37°C followed by 40 min at room temperature with 3 nM (WT) or 6 nM (R43Q) [ 3 H]FNZM in the presence of seven different GABA concentrations ranging from 30 nm-100 M (final volume 250 l) and then filtered as described above. Data were fit using non-linear regression analysis to a sigmoidal dose response curve described by the equation 4 , 0.5 mM MgCl 2 , 137 mM NaCl, and 14 mM Na 2 HPO 4 , pH 7.1) and incubated with the non-membrane permeable biotinylation reagent NHS-LC (or SS)-Biotin (0.3-0.5 mg/ml in PBS, Pierce) for 30 min at 4°C to label surface membrane proteins. To quench the reaction, cells were incubated with 10 mM glycine in PBS (10 min at room temperature). Sulfhydryl groups were blocked by incubating the cells with 5 mM N-ethylmaleimide in PBS (15 min at room temperature). Cells were solubilized (overnight at 4°C) in lysis buffer (1% Triton X-100, 50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, pH 7.5) supplemented with protease inhibitors (0.5 mg/ml Pefabloc, 1 g/ml pepstatin, 1 g/ml leupeptin, Roche Applied Science) and 5 mM N-ethylmaleimide. Lysates were cleared by centrifugation (16,000 ϫ g, 10 min at 4°C) and lysate protein concentration was determined using a BCA protein assay (Pierce). A sample of each lysate (equal protein concentrations) was prepared for SDS-PAGE and Western blot analysis by adding 2ϫ Laemmli sample buffer (LSB) ϩ 6 M Urea ϩ 100 mM dithiothreitol. Biotinylated surface proteins were affinity purified from the remaining cell lysates by incubating (1 h at 4°C, rotating) with 100 l of Immobilized Neutravidin-conjugated agarose bead slurry (Pierce). The samples were then centrifuged (16,000 ϫ g, 10 min at 4°C), and the beads were washed (six times) with buffer (0.1 or 0.5% Triton X-100, 50 mM Tris-Cl, 150 mM NaCl, and 5 mM EDTA, pH 7.5). Surface proteins were eluted from the beads with 200 l of LSB/urea buffer (6% SDS, 20% glycerol, 100 mM dithiothreitol, and 6 M urea, pH 6.8).
Western Blotting-Protein samples were run on 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes (0.45 micron). Blots were incubated overnight at 4°C in blocking buffer containing 2% nonfat milk in TTBS (500 mM NaCl, 20 mM Tris base, 0.05% Tween-20, pH 7.5). Blots were washed once in TTBS (5 min at room temperature) and incubated (1 h at room temperature) in ␥ 2 -(1-33) or ␤ 2/3 primary antibody at dilutions of 1:250 or 1: 100 in blocking buffer, respectively. The anti-␥ 2 -(1-33) rabbit polyclonal antibody was provided as a generous gift by Dr. Werner Sieghart (University Clinic for Psychiatry, Vienna, Austria) and the anti-␤ 2/3 mouse monoclonal antibody was purchased from Upstate Biotechnology (Lake Placid, NY). Following incubation in primary antibody, the blots were washed (3 ϫ 10 min) with TTBS and then incubated (1 h at room temperature) in horseradish peroxidase-conjugated goat-anti-rabbit IgG (for anti-␥ 2 , Pierce) or horseradish peroxidase-conjugated goat-anti-mouse (for anti-␤ 2 , Pierce) at a dilution of 1:10, 000 in blocking buffer. The blots were then washed (6 ϫ 5 min) in TTBS and developed with either SuperSignal West Pico or West Femto chemiluminescent substrates (Pierce) for visualization of ␥ 2 and ␤ 2 subunits, respectively. A background eliminator was applied to exposed films to remove excessive levels of background signal to better visualize the pertinent bands (Erase-It TM Background Eliminator, Pierce).
Immunofluorescence-Cells used for immunofluorescence were transfected without pAdvantage, incubated overnight at 31°C (5% CO 2 ) and then re-plated on poly-D-lysine-coated glass coverslips and returned to the incubator for an additional 24 h at 37°C. Cells were washed and fixed in 2% paraformaldehyde in PBS. For membrane permeabilization, cells were incubated with 0.1% Triton X-100 (v/v) in PBS for 10 min at room temperature. Cells were then washed three times with PBS, blocked for 15-20 min with PBS containing 20% goat serum, and incubated in anti-␥ 2 antibody (diluted 1:500 in blocker) overnight at 4°C; this was followed by three washes with PBS. Cells were then incubated for 1 h (at room temperature) with Alexa Fluor® 488 goat anti-rabbit IgG (Molecular Probes, Eugene, OR) diluted 1:1000 in blocker. Cells were washed three times with PBS and mounted onto glass slides. In some cases, both permeabilized and intact cells were incubated in secondary antibody only to determine nonspecific labeling. Fluorescently labeled cells were imaged using a Bio-Rad MRC-1024 laser scanning confocal microscope with a ϫ40 lens. Gain settings were normalized to cells treated with secondary antibody only (such that no fluorescent signal was detected in these controls) and the same gain and laser power settings were used for subsequent analysis of WT and mutant receptor expressing cells labeled with both primary and secondary antibodies. (Fig. 1A) . Thus, it is possible that the mutation alters not only expression but also the function of ␣ 1 ␤ 2 ␥ 2 R43Q GABARs. Although the K d values for muscimol and flunitrazepam were unaltered by the mutation, we speculated that the mutation could disrupt cross-talk (i.e. coupling) between the BZD and GABA binding sites. To address this possibility, we assessed the ability of GABA to potentiate (Table II) .
RESULTS
The Effect of
Furthermore, the concentrations of GABA needed to elicit halfmaximal potentiation of [ 3 H]FNZM binding (EC 50 ) for WT and mutant receptors were equivalent (Table II) . These findings indicate first that the R43Q mutation does not alter the apparent affinity for GABA and second that the mutation leaves the allosteric coupling between the BZD and GABA binding sites intact.
The Effect of ␥ 2 R43Q on Cell Surface Expression of ␥ 2 and ␤ 2 Subunits-Whereas the radioligand binding data suggest a selective decrease in ␥ 2 subunit-containing receptors, the data reflect binding to membrane homogenates that contain assembled and partially assembled intracellular receptors as well as fully assembled cell surface receptors. To directly determine the effect of ␥ 2 R43Q on surface GABAR expression, we compared total and surface expression of ␥ 2 and ␤ 2 subunits by Western blot analysis. Surface proteins of intact cells were labeled with the NHS-biotin and affinity-purified using avidinconjugated agarose beads. When probed with anti-␥ and anti-␤ GABAR antibodies, blots of surface protein from cells expressing WT ␣ 1 ␤ 2 ␥ 2 receptors displayed significant amounts of ␥ 2 and ␤ 2 subunit immunoreactivity (Fig. 3) . Expression of ␣ 1 ␤ 2 ␥ 2 R43Q receptors decreased surface ␤ 2 subunit immunoreactivity to 42 Ϯ 15.7% of WT surface ␤ 2 labeling (as measured by densitometry, n ϭ 3) and almost completely abolished the surface ␥ 2 subunit signal to 2.7% Ϯ 1.3% of WT surface ␥ 2 labeling (n ϭ 6, Fig. 3 ). Western blots of total protein lysates (cell surface and intracellular proteins) showed no significant differences in ␤ 2 or ␥ 2 subunit immunoreactivities between cells expressing WT and mutant receptors. These findings suggest that although the ␥ 2 R43Q mutation does not alter the total amount of ␥ 2 subunit proteins produced within the cell, it does cause a significant decrease in the fraction of the total ␥ 2 subunit protein pool expressed on the cell surface. Whereas a decrease in surface ␤ 2 signal was observed from cells expressing ␣ 1 ␤ 2 ␥ 2 R43Q receptors compared with WT receptors (58 Ϯ 15.7%), the decrease in signal was significantly less (p Ͻ 0.05, Mann-Whitney) than the decrease seen in ␥ 2 subunit reactivity (97 Ϯ 1.3%) and suggests that ␣ 1 ␤ 2 pentameric receptors are being formed and expressed on the cell surface (see "Discussion").
To verify the loss of ␥ 2 -containing surface receptors, cell surface expression of WT and mutant ␥ 2 subunits was assayed by immunostaining intact cells with an anti-␥ subunit antibody and a fluorescently tagged secondary antibody. Cells expressing WT ␣ 1 ␤ 2 ␥ 2 receptors displayed robust ␥ 2 subunit labeling on the cell surface (Fig. 4, A and B , are two representative 40ϫ fields depicting ␥ 2 staining of intact HEK cells expressing WT receptors). In cells expressing ␣ 1 ␤ 2 ␥ 2 R43Q receptors, the intensity of the ␥ 2 subunit cell surface staining as well as the number of cells labeled were dramatically reduced relative to WT-expressing cells, confirming that the ␥ 2 R43Q mutation caused a reduction in ␥ 2 subunit-containing GABARs expressed on the cell surface (Fig. 4 , C and D, are two representative 40ϫ fields illustrating ␥ 2 staining of intact cells expressing mutant ␣ 1 ␤ 2 ␥ 2 R43Q receptors, where the total number of cells in each panel under bright field are comparable with the number of cells in Fig. 4, A and B) . In permeabilized cells expressing either WT (Fig. 4E) or mutant ␣ 1 ␤ 2 ␥ 2 R43Q receptors (Fig. 4F) , intense perinuclear fluorescent staining of the ␥ 2 subunit was observed indicating that the mutant ␥ 2 R43Q subunit was being produced in similar quantities as WT ␥ 2 subunit. Perinuclear staining was seen in permeabilized cells expressing either WT or mutant receptors, which is consistent with an endoplasmic reticulum localization of the ␥ 2 subunit. 
R43Q (lanes B and D)
GABARs probed with anti-␤ 2 antibody. The experiment was performed three times with similar results. Cell Surface represents affinity-purified cell surface protein. Total represents samples of equal protein concentration from whole cell lysates (surface ϩ intracellular protein). In the above blots, as determined by densitometry, the ␥ 2 R43Q mutation decreased ␥ 2 surface immunoreactivity 97.5% as compared with wild-type transfections and decreased ␤ 2 surface immunoreactivity 69%. Thus, the ␥ 2 R43Q mutation decreases ␥ 2 surface immunoreactivity to a greater extent than ␤ 2 surface immunoreactivity. 
DISCUSSION
The goal of this study was to evaluate the functional effect of the GABAR ␥ 2 R43Q mutation linked to human epilepsy. We demonstrate that the main effect of the ␥ 2 R43Q mutation is to reduce surface expression of ␣ 1 ␤ 2 ␥ 2 R43Q receptors while leaving the pharmacology and functional coupling between GABA and BZD binding sites of the receptor intact. As discussed below, our data both extend previous findings and help clarify the inconsistencies in the reported electrophysiological effects of this mutation.
Using two electrode voltage clamp recording techniques and expression in Xenopus laevis oocytes, Wallace et al. (13) reported no differences in GABA evoked current amplitude or GABA EC 50 but observed a complete abolition in the ability of diazepam to potentiate GABA current in mutant receptors compared with wild-type receptors and suggested that the mutation disrupted BZD binding. Although the observed inability of diazepam to potentiate GABA current in mutant receptors may suggest an alteration in BZD binding (i.e. altered BZD binding affinity), it could also result from the uncoupling of GABA and BZD binding sites resulting in a loss of BZD modulation of GABA-activated current or from a reduction in the relative expression of ␣ 1 ␤ 2 ␥ 2 containing GABARs as compared with ␣ 1 ␤ 2 receptors, which are not modulated by BZDs but are still activated by GABA. Our results indicate that the ␥ 2 R43Q mutation disrupts expression of ␥ 2 containing GABARs as evidenced by the decrease in cell surface amounts of ␥ 2 subunit (Figs. 3 and 4) and the 75% reduction in the total number of binding sites for the BZD [
3 H]FNZM in cells expressing mutant receptors (Fig. 1) (Figs. 1 and 3) . Thus, it is unlikely that the loss of BZD sensitivity observed by Wallace et al. (13) and the decrease in BZD sensitivity observed by Bowser et al. (14) are caused by alterations in BZD binding affinity or the functional coupling between the BZD and GABA binding sites but may instead be the result of a reduction in the relative expression of ␣ 1 ␤ 2 ␥ 2 R43Q containing GABARs as compared with ␣ 1 ␤ 2 receptors. Alternatively, the differences between our data and those of Wallace et al. (13) may be caused by different expression systems (HEK 293 cells versus oocytes).
Interestingly, in cells expressing ␣ 1 ␤ 2 ␥ 2 R43Q receptors, we observed a decrement in the level of ␤ 2 subunit expressed on the cell surface in addition to the almost complete loss of surface ␥ 2 subunit (Fig. 3B) . This observation raises the intriguing possibility that the ␥ 2 R43Q mutation has a dominant negative effect on surface GABAR expression in that it may hamper the expression of ␣ 1 ␤ 2 GABARs as well as ␣ 1 ␤ 2 ␥ 2 receptors. Although our binding data demonstrate that the total number of muscimol binding sites is not affected by the ␥ 2 R43Q mutation (Fig. 1) , the data reflect binding to membrane homogenates that contain assembled and partially assembled intracellular receptors as well as fully assembled cell surface receptors. Intracellular and incompletely assembled receptors containing ␣ and ␤ subunits bind muscimol with similar high affinity (ϳ10 nM) as fully assembled pentameric receptors (19) . As such, any small decrement in cell surface expression could be compensated by muscimol binding to a larger pool of intracellular assembly intermediates, hence explaining the comparable levels of muscimol binding between membranes prepared from cells expressing mutant and WT receptors. This possibility is supported by the finding that in the absence of ␥ subunits, ␣ and ␤ subunits have a greater propensity to form assembly intermediates (19, 20) .
Why a similar phenomenon is not observed for flunitrazepam binding can be explained by the finding that ␣␥ assembly intermediates, though viable, possess a 100-fold lower affinity for flunitrazepam than fully formed ␣␤␥ pentamers (19) . Our filtration binding assays would not detect the low affinity sites associated with assembly intermediates. Our assay preferentially detects high affinity flunitrazepam binding to pentameric receptors and thus the 75% decrease in flunitrazepam binding observed reflects a decrease in ␣␤␥ pentameric receptors. Whereas the mutant ␥ 2 subunit may still be able to assemble individually with ␣ 1 or ␤ 2 subunits (forming ␣ 1 ␥ 2 or ␤ 2 ␥ 2 assembly intermediates), the ␥ 2 subunit mutation could prevent assembly and/or targeting of fully assembled pentameric receptor complexes, thus tagging or targeting both mutant ␥ and the associated ␣ or ␤ subunits for intracellular sequestration FIG. 5 . Model of the extracellular ␣ 1 / ␥ 2 /␤ 2 subunit interfaces of the GA-BAR. The ␣ 1 subunit is white, the ␥ 2 subunit is yellow, and the ␤ 2 subunit is blue. Several residues are highlighted; ␥ 2 F77 is located at the BZD binding site (␣ 1 /␥ 2 interface) whereas ␥ 2 R43 is located at the ␥ 2 /␤ 2 subunit interface. Inset, putative salt bridge interactions (green dashed lines) between ␥ 2 R43, ␥ 2 E178, and ␤ 2 R117. and/or degradation. In this way, the ␥ 2 subunit could sequester some ␣ 1 and ␤ 2 subunits that would otherwise form "normal" and functional ␣ 1 ␤ 2 heteropentameric receptors that would be expressed on the cell surface.
Nevertheless, significant amounts of the ␤ 2 subunit were detected in surface protein purified from cells expressing mutant receptors (Fig. 3B) indicating that fully formed ␣ 1 ␤ 2 pentameric receptors are being expressed on the cell surface. It is not likely that the ␤ 2 subunits detected on the cell surface are incorporated into anything other than pentamers, as previous studies have shown that partially assembled receptor intermediates containing ␣␥, ␣␤, or ␤␥ subunits are not expressed on the cell surface (19) . In electrophysiological studies (14, 15) , GABA-evoked currents were measured from HEK 293 cells co-expressing wild-type ␣, ␤, and mutant ␥ 2 R43Q subunits, indicating expression of some ␤ 2 subunit containing receptors on the cell surface. Our data, however, suggest a decrease in surface GABAR protein in cells expressing the mutant ␥ 2 R43Q subunit compared with cells expressing WT subunits. This is consistent with results reported in Bianchi et al. (15) , where HEK 293 cells expressing mutant ␥ 2 R43Q subunits displayed reduced GABA current amplitudes.
A recent study by Bowser et al. (14) , using rapid drug application and patch-clamp recordings of HEK 293 cells expressing mutant receptors found that ␣ 1 ␤ 2 ␥ 2 R43Q receptors displayed slowed deactivation, an increase in the fast component of desensitization, and an increase in paired-pulse desensitization, indicating that the mutation altered receptor kinetics. In contrast, a paper by Bianchi et al. (15) , using a similar recording technique and cell expression system, reported no differences in macroscopic GABAR kinetics or diazepam potentiation of GABA current in ␣ 1 ␤ 3 ␥ 2L R43Q receptors but observed reductions in peak GABA-induced currents instead. It is unclear why the ␥ 2 R43Q mutation had different effects on GABAR current responses in the Bowser et al. (14) and Bianchi et al. (15) studies. One possible explanation for these conflicting findings is that different receptor subunit subtypes were expressed in the two studies. Regardless, our data, using biochemical approaches, directly demonstrate that one of the main effects of the ␥ 2 R43Q mutation is to reduce cell surface ␣ 1 ␤ 2 ␥ 2 receptor expression. However, because the equilibrium radioligand binding techniques used in this study cannot resolve alterations in receptor kinetics, it is certainly possible that the ␣ 1 ␤ 2 ␥ 2 R43Q receptors that are expressed have altered kinetic properties.
A homology model of the N-terminal region of the GABAR based on the crystal structure of the homologous acetylcholine binding protein (21) localizes ␥ 2 R43 to the ␥/␤ subunit interface (Fig. 5) and not the BZD binding site interface (␣/␥). The ␥ 2 R43Q mutation does not affect BZD or GABA apparent binding affinities, which supports the prediction that ␥ 2 R43Q is not involved in forming the BZD or GABA binding pockets and also indicates that the mutation does not have an indirect allosteric effect on BZD or GABA apparent binding affinities. Our data demonstrate that ␥ 2 R43 is important for efficient cell surface expression of GABARs. ␥ 2 R43 is conserved not only in all GABAR subunit subtypes, but also in the subunits of other members of the ligand gated ion channel superfamily. The absolute conservation of this arginine points to a structural role. By mutating ␥ 2 Arg 43 to Glu, putative electrostatic interactions with a nearby negatively charged residue (␥ 2 E178) and a positively charged residue on the neighboring ␤ 2 subunit (R117) may be disrupted (Fig. 5) , thus preventing the stable or successful incorporation of the ␥ 2 subunit into a pentamer (22) .
Although the idea that a single residue could have such an impact on cell surface expression may seem dubious, the concept is not unprecedented. Recently, a single residue (Ser-171) in the ␥ 2 subunit when mutated to glycine or cysteine has been found to completely abolish cell surface expression and assembly of ␣ 2 ␤ 1 ␥ 2 GABARs (23). It is also equally possible that ␥ 2 R43 is part of a larger assembly motif that when altered disrupts the assembly of the ␥ 2 subunit with either ␣ 1 or ␤ 2 subunits. Previous experiments have shown that residues within the N-terminal domain of the ␥ 2 subunit are critical for selective subunit assembly and subunit arrangement (24, 25) . Although the underlying mechanism responsible for reduced cell surface expression of ␥ 2 R43Q subunit containing GABARs is unclear (e.g. misfolding, reduced subunit assembly, reduced surface membrane receptor targeting, increased degradation), the ␥ 2 subunit is indispensable for the maintenance of GABARs at synapses (26) . As such, the decrease in surface expression of ␥ 2 containing receptors by the ␥ 2 R43Q mutation would likely blunt synaptic inhibitory neurotransmission, thereby contributing to neuronal hyperexcitability and hence the etiology of epilepsy.
